ArticleJournal of the National Cancer Center2023
Benefits and harms of screening for hepatocellular carcinoma in high-risk populations: systematic review and meta-analysis.
Article in Journal of the National Cancer Center, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Novel diagnostic and therapeutic strategies based on PANoptosis for hepatocellular carcinoma.Cancer biology & medicine · 2025Pooled it
- Efficacy and safety of transarterial chemoembolization (TACE) with tislelizumab and tyrosine kinase inhibitors versus TACE for intermediate and advanced HCC.Journal of cancer research and clinical oncology · 2026Article
- Hepatocellular Carcinoma Masquerading as Heart Failure: When POCUS "Incidentally" Detects Cancer.POCUS journal · 2026Article
- Prognostic value of lymphatic vessel density in the capsule of early-stage hepatocellular carcinoma: implications for postoperative recurrence risk.Frontiers in immunology · 2026Article
- Effectiveness of early cancer screening and diagnosis in urban China.Scientific reports · 2025Article
- Activation of lymphangiogenesis by platelet as novel therapeutic approaches for liver cirrhosis and portal hypertension.World journal of gastroenterology · 2025Article
- Reply to: "Surveillance for hepatocellular carcinoma in patients with primary biliary cholangitis: For all or just for some?"JHEP reports : innovation in hepatology · 2025Article
- Impact of frailty on the long-term prognosis of the elderly with hepatocellular carcinoma treated with transarterial chemoembolization.Scientific reports · 2025Article
- SLC7A11, a disulfidptosis-related gene, correlates with multi-omics prognostic analysis in hepatocellular carcinoma.European journal of medical research · 2025Article
- The causal relationship between eosinophil counts and hepatocellular carcinoma in East Asians: evidence from a Mendelian randomization study.Discover oncology · 2025Article
- Mechanistic link between long noncoding RNA and stability of oncogene reveals stemness and chemoresistance of hepatocellular carcinoma.World journal of gastroenterology · 2025Article
- Application of CT-based radiomics combined with laboratory tests such as AFP and PIVKA-II in preoperative prediction of pathologic grade of hepatocellular carcinoma.BMC medical imaging · 2025Article
- Key oncogenes and candidate drugs for hepatitis-B-driven hepatocellular carcinoma progression.Discover oncology · 2025Article
- Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment.Clinical and molecular hepatology · 2025Review
- Mutual causal effects between immune cells and hepatocellular carcinoma: a Mendelian randomization study.Discover oncology · 2025Article
- Impact of Middle Hepatic Vein Resection During Hemihepatectomy on Surgical Outcomes and Long-Term Prognosis in Hepatocellular Carcinoma: A Retrospective Study.Journal of hepatocellular carcinoma · 2025Article
- Burden of liver cancer resulting from different etiologies in China from 1990 to 2021 and prediction to 2031.PloS one · 2025Article
- Trends of primary liver cancer incidence and mortality in the United States: A population-based study over the last four decades.PloS one · 2024Article
- Effectiveness and safety of vascular intervention plus lenvatinib versus vascular intervention alone for hepatocellular carcinoma patients with portal vein tumor thrombus: a retrospective comparative study.Frontiers in oncology · 2024Article
- Hepatocellular carcinoma in HBsAg seroclearance: clinical features, recurrence, and prognosis following curative hepatectomy.Therapeutic advances in medical oncology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The incidence and mortality of hepatocellular carcinoma (HCC) have been increasing around the world. Current guidelines recommend HCC screening in high-risk population. However, the strength of evidence of benefits and harms of HCC screening to support the recommendation was unclear. The objective is to systematically synthesize current evidence on the benefits and harms of HCC screening. Methods: We searched PubMed and nine other databases until August 20, 2021. We included cohort studies and RCTs that compared the benefits and harms of screening and non-screening in high-risk population of HCC. Case series studies that reported harms of HCC screening were also included. Pooled risk ratio (RR), according to HCC screening status, was calculated for each benefit outcome (e.g., HCC mortality, survival rate, proportion of early HCC), using head-to-head meta-analysis. The harmful outcomes (e.g., proportion of physiological harms provided by non-comparative studies were pooled by prevalence of meta-analysis. Analysis on publication bias and quality of life, subgroup analysis, and sensitivity analysis were also conducted. Results: We included 70 studies, including four random clinical trials (RCTs), 63 cohort studies,three case series studies. The meta-analysis of RCTs showed HCC screening was significantly associated with reduced HCC mortality (RR [risk ratio], 0.73 [95% CI, 0.56-0.96]; Conclusion: The existing evidence suggests HCC screening is more effective than non-screening in high-risk population. However, harms of screening should not be ignored.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.